Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Up 93.6% in November

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,500,000 shares, a growth of 93.6% from the November 15th total of 774,700 shares. Based on an average daily trading volume, of 16,110,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.7% of the company’s stock are short sold.

Insider Buying and Selling at Tevogen Bio

In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the sale, the insider now owns 4,254,302 shares of the company’s stock, valued at approximately $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 56.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. purchased a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Stock Up 2.2 %

Shares of TVGN opened at $1.02 on Thursday. Tevogen Bio has a one year low of $0.26 and a one year high of $21.09. The business has a fifty day moving average of $1.42 and a 200 day moving average of $0.91.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.